What is the recommended treatment for a cough, including antiviral therapy for suspected influenza and symptomatic cough relief?

Treatment for Cough

For cough suspected to be influenza, start antiviral treatment immediately with oseltamivir (oral), zanamivir (inhaled), or peramivir (IV) for 5 days in high-risk patients, hospitalized patients, or those with severe/progressive illness, without waiting for test confirmation 1.

When to Treat with Antivirals

Start antiviral therapy as soon as possible (ideally within 48 hours of symptom onset, though benefit is greatest within 24 hours) for:

• Any hospitalized patient with suspected influenza, regardless of illness duration 1
• High-risk outpatients: chronic medical conditions, immunocompromised, children <2 years, adults ≥65 years, pregnant women and up to 2 weeks postpartum 1
• Any patient with severe or progressive illness, regardless of age or illness duration 1

For otherwise healthy, low-risk outpatients, antiviral treatment can be considered but is optional 1. Recent evidence shows baloxavir may reduce hospital admission risk in high-risk patients (1.6% absolute reduction) and probably reduces symptom duration by about 1 day, while oseltamivir probably has minimal effect on symptom duration (0.75 days) 2.

Antiviral Drug Selection

Use a single neuraminidase inhibitor (NAI)—do not combine multiple antivirals 1:

• Oseltamivir (oral): 5-day course for uncomplicated influenza 1
• Zanamivir (inhaled): 5-day course 1
• Peramivir (IV): single dose 1
• Baloxavir: emerging evidence suggests it may be preferred for high-risk patients based on reduced hospitalization risk and fewer adverse events 2

Do not use higher than FDA-approved doses routinely 1. Consider longer treatment duration for immunocompromised patients or those with severe lower respiratory disease (pneumonia, ARDS) due to prolonged viral replication 1.

Symptomatic Cough Relief

The approach differs dramatically based on cough etiology:

For Chronic Bronchitis:

• Peripheral cough suppressants (levodropropizine, moguisteine): recommended for short-term symptomatic relief 3
• Central cough suppressants (codeine, dextromethorphan): recommended for short-term relief 3
• Ipratropium bromide (inhaled): the only anticholinergic recommended for cough suppression 3

For Upper Respiratory Infection (Common Cold):

• Do NOT use peripheral or central cough suppressants—they have limited efficacy 3
• Do NOT use zinc preparations 3
• Do NOT use over-the-counter combination cold medications (except older antihistamine-decongestant combinations) 3
• Do NOT use albuterol for cough not due to asthma 3

Critical Pitfall: Bacterial Coinfection

Investigate and empirically treat bacterial coinfection in influenza patients who:

• Present initially with severe disease (extensive pneumonia, respiratory failure, hypotension, fever) 1
• Deteriorate after initial improvement, particularly if on antivirals 1
• Fail to improve after 3-5 days of antiviral treatment 1

However, avoid unnecessary antibiotics: 30% of influenza patients receive antibiotics inappropriately, while only 15-16% receive appropriate antiviral therapy 4. This represents a major quality gap in care.

Diagnostic Testing Considerations

For hospitalized patients with suspected influenza:

• Use RT-PCR or molecular assays (not rapid antigen tests or immunofluorescence) 1
• Do not delay antiviral treatment while awaiting test results—treat empirically based on clinical suspicion 1, 5
• If rapid tests or immunofluorescence are negative, confirm with RT-PCR 1

For outpatients, clinical diagnosis is sufficient and laboratory confirmation is unnecessary in most cases 5. Testing may be useful when confirmation would change treatment decisions 1.

Key Evidence Nuances

The 2019 IDSA guidelines 1 provide the strongest framework, but the 2025 WHO guidance 6 and recent network meta-analysis 2 suggest baloxavir may offer advantages over oseltamivir for high-risk patients. The ACCP guidelines 3 clearly demonstrate that most over-the-counter cough remedies lack efficacy for viral URIs, making targeted antiviral therapy for influenza the priority when clinically indicated.

Avoid the common error of prescribing antibiotics for viral cough while withholding appropriate antivirals—this pattern occurs in approximately 30% vs 15% of cases respectively 4, representing suboptimal care that increases antibiotic resistance without improving outcomes.